NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

APLS

Apellis Pharmaceuticals Inc

Jul 07 • 04:00PM ET

17.42

Dollar change -0.84
Percentage change -4.60	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN SRPT MRNA BMRN EXEL VRTX PBYI UTHR KURA

| Held by: VTI VB XBI VXF VBK IWP IBB SCHA IWF IWR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.79	Insider Own	17.70%	Shs Outstand	125.66M	Perf Week	-0.06%
Market Cap	2.19B	Forward P/E	-	EPS next Y	-0.66	Insider Trans	-0.46%	Shs Float	103.43M	Perf Month	-5.89%
Enterprise Value	2.30B	PEG	-	EPS next Q	-0.48	Inst Own	100.06%	Short Float	24.31%	Perf Quarter	-22.65%
Income	-223.68M	P/S	2.82	EPS this Y	2.91%	Inst Trans	2.52%	Short Ratio	9.95	Perf Half Y	-45.41%
Sales	775.84M	P/B	13.33	EPS next Y	57.70%	ROA	-27.29%	Short Interest	25.14M	Perf YTD	-45.41%
Book/sh	1.31	P/C	6.08	EPS next 5Y	-	ROE	-103.82%	52W High	42.47 -58.98%	Perf Year	-50.20%
Cash/sh	2.86	P/FCF	-	EPS past 3/5Y	43.47% 20.08%	ROIC	-35.68%	52W Low	16.10 8.20%	Perf 3Y	-61.45%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	127.27% -	Gross Margin	82.83%	Volatility	4.27% 4.05%	Perf 5Y	-43.39%
Dividend TTM	-	EV/Sales	2.96	EPS Y/Y TTM	48.16%	Oper. Margin	-24.00%	ATR (14)	0.82	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.62	Sales Y/Y TTM	48.04%	Profit Margin	-28.83%	RSI (14)	43.43	Recom	1.91
Dividend Gr. 3/5Y	- -	Current Ratio	4.08	EPS Q/Q	-36.08%	SMA20	-4.87%	Beta	0.75	Target Price	35.40
Payout	-	Debt/Eq	2.86	Sales Q/Q	-3.21%	SMA50	-3.97%	Rel Volume	0.63	Prev Close	18.26
Employees	710	LT Debt/Eq	2.82	Earnings	May 07 BMO	SMA200	-32.00%	Avg Volume	2.53M	Price	17.42
IPO	Nov 09, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-114.87% -14.01%	Trades		Volume	1,583,654	Change	-4.60%

Date	Action	Analyst	Rating Change	Price Target Change
May-09-25	Downgrade	Raymond James	Strong Buy → Outperform	$52
May-09-25	Downgrade	BofA Securities	Buy → Neutral	$23
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$44
Dec-17-24	Downgrade	Goldman	Buy → Neutral	$36
Nov-21-24	Initiated	Morgan Stanley	Equal-Weight	$31
Oct-25-24	Initiated	RBC Capital Mkts	Sector Perform	$25
Oct-16-24	Initiated	William Blair	Outperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
May-31-24	Initiated	Piper Sandler	Neutral	$46
Feb-05-24	Upgrade	Jefferies	Hold → Buy	$68 → $80
Dec-14-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-09-23	Initiated	Goldman	Buy	$74
Nov-02-23	Initiated	Mizuho	Neutral	$42
Oct-06-23	Upgrade	JP Morgan	Neutral → Overweight	$60 → $81
Sep-15-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$34 → $64
Aug-29-23	Reiterated	Citigroup	Buy	$45 → $54
Aug-03-23	Downgrade	JP Morgan	Overweight → Neutral	$72 → $60
Aug-01-23	Downgrade	BofA Securities	Buy → Neutral	$114 → $40
Jan-03-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$83 → $58
Nov-10-22	Downgrade	Jefferies	Buy → Hold	$70 → $40

Show Previous Ratings

Jul-06-25 04:15AM	Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating (Insider Monkey)
Jul-02-25 10:08PM	Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing (Insider Monkey)
10:32AM	Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli (Zacks)
Jul-01-25 07:40AM	Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan) (PR Newswire)
07:00AM	Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli (systemic pegcetacoplan) (GlobeNewswire)
11:30AM	Loading…
Jun-13-25 11:30AM	Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report? (Zacks)
Jun-09-25 05:31AM	Sobi and Apellis report new data from Phase III trial for C3G and IC-MPGN (Clinical Trials Arena)
Jun-07-25 09:25AM	Apellis, Sobi present data from open-label period of Phase 3 VALIANT study (TipRanks)
Jun-06-25 11:31AM	Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report? (Zacks)
09:15AM	Apellis and Sobi Announce EMPAVELI (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN (GlobeNewswire)
Jun-04-25 07:00AM	Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-25 02:23AM	Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday (Insider Monkey)
May-09-25 10:35AM	Apellis price target lowered to $20 from $28 at Scotiabank (TipRanks)
09:18AM	Apellis Pharmaceuticals downgraded by Raymond James due to added uncertainty (Investing.com)
08:46AM	Is Apellis Pharmaceuticals, Inc. (APLS) The Best Stock That Will Bounce Back? (Insider Monkey)
10:43AM	Loading…
May-08-25 10:43AM	Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
03:13AM	Apellis Pharmaceuticals Inc (APLS) Q1 2025 Earnings Call Highlights: Strong Market Leadership ... (GuruFocus.com)
12:45AM	Q1 2025 Apellis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-07-25 06:09PM	Why Apellis Pharmaceuticals Wilted on Wednesday (Motley Fool) -5.91%
01:18PM	Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:10AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-06-25 07:00AM	Apellis Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-05-25 08:15AM	Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-30-25 10:01AM	Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know (Zacks) +5.49%
07:00AM	Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 08:24PM	Is Apellis Pharmaceuticals, Inc. (APLS) the Best Oversold NASDAQ Stock to Buy Right Now? (Insider Monkey)
10:01AM	Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-23-25 12:56PM	Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
07:00AM	Loading…
Apr-21-25 07:00AM	Apellis Announces Craig Wheeler to Join the Board of Directors (GlobeNewswire)
Apr-15-25 07:20AM	BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock? (Zacks)
Apr-02-25 09:11AM	APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag (Zacks)
04:55AM	FDA accepts priority review of Apellis Empaveli sNDA for kidney diseases (Pharmaceutical Technology)
Apr-01-25 07:00AM	Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI (pegcetacoplan) for C3G and Primary IC-MPGN (GlobeNewswire)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-25-25 05:41PM	Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
Mar-22-25 11:41AM	Morgan Stanley says Fabhaltas label leaves opportunity for Apellis Empaveli (TipRanks)
Mar-21-25 01:13PM	Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy (SeekingAlpha)
Mar-05-25 02:04PM	Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst (Benzinga)
Mar-01-25 02:08AM	Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
01:29AM	Q4 2024 Apellis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-28-25 09:30AM	Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics (Zacks)
08:15AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:05AM	Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-27-25 07:11AM	What To Expect From Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings (GuruFocus.com)
Feb-24-25 07:00AM	Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-23-25 01:31PM	Why Apellis Pharmaceuticals, Inc. (APLS) is the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-21-25 10:00AM	Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-20-25 12:08PM	Is Apellis Pharmaceuticals (APLS) One of the Most Oversold Healthcare Stocks to Buy Now? (Insider Monkey)
02:00AM	Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli (pegcetacoplan) for C3G and Primary IC-MPGN (GlobeNewswire)
Feb-18-25 04:12PM	Apellis Pharmaceuticals (APLS): Among Top Insider Stock Buys And Sells In January (Insider Monkey)
Feb-14-25 07:00AM	Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-11-25 02:03PM	Why Insiders Are Selling Apellis Pharmaceuticals, Inc. (APLS) Recently (Insider Monkey)
Feb-04-25 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.52%
Jan-27-25 04:00PM	Apellis Receives Approval of SYFOVRE (pegcetacoplan) in Australia for Geographic Atrophy (GA) (GlobeNewswire)
Jan-13-25 09:00AM	Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-10-25 07:00AM	Apellis Announces Keli Walbert to Join the Board of Directors (GlobeNewswire) -16.85%
Jan-07-25 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-06-25 07:00AM	Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-24 09:35AM	Should You Hold Apellis Pharmaceuticals (APLS)? (Insider Monkey)
Dec-06-24 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-05-24 11:30AM	Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report? (Zacks)
Nov-27-24 07:00AM	Apellis Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 07:00AM	Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-24 06:31AM	Apellis price target lowered to $30 from $43 at Wells Fargo (TipRanks)
06:25AM	Apellis price target lowered to $47 from $61 at BofA (TipRanks)
Nov-06-24 02:10AM	Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com)
Nov-05-24 04:47PM	Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday (Motley Fool)
09:30AM	Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
09:24AM	Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales (Investor's Business Daily)
08:20AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:05AM	Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-04-24 07:04AM	Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Oct-30-24 06:00AM	Axonis Therapeutics Announces $115 Million Series A Financing (PR Newswire)
Oct-29-24 10:01AM	Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
05:51AM	1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst (Motley Fool)
Oct-28-24 08:40AM	Apellis, Sobi announced results from Phase 3 VALIANT study (TipRanks)
Oct-26-24 02:00PM	Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN (GlobeNewswire)
Oct-22-24 07:00AM	Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-16-24 02:56PM	Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch (Benzinga)
07:00AM	Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN (GlobeNewswire)
Oct-04-24 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-03-24 10:19AM	Should You Hold Apellis Pharmaceuticals (APLS)? (Insider Monkey)
Sep-25-24 07:00AM	Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day (GlobeNewswire)
Sep-20-24 04:10PM	Apellis Stock Hammered After Eye Drug Gets A Third European Rejection (Investor's Business Daily) -11.49%
06:17AM	Apellis eye drug again turned back in Europe (BioPharma Dive)
05:00AM	Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination (GlobeNewswire)
Sep-14-24 07:36PM	Apellis Pharmaceuticals, Inc. (APLS): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-06-24 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 11:57PM	Apellis Pharmaceuticals, Inc. (APLS): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 07:00AM	Apellis Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 07:15AM	Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024 (InvestorPlace)
Aug-09-24 04:32AM	Sobi and Apellis report positive topline results from Phase III pegcetacoplan study (Clinical Trials Arena)
Aug-08-24 07:57AM	Apellis plans FDA filing after drug success in kidney trial (BioPharma Dive) +12.12%
07:32AM	Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN (PR Newswire)
07:00AM	Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN (GlobeNewswire)
Aug-06-24 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-01-24 10:01AM	Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues (Zacks) -9.09%

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Watson David O.	General Counsel	Jun 16 '25	Sale	18.77	5,000	93,850	133,730	Jun 18 08:49 AM
Watson David O.	Officer	Jun 16 '25	Proposed Sale	18.77	5,000	93,850		Jun 16 10:38 AM
Deschatelets Pascal	Chief Scientific Officer	May 21 '25	Option Exercise	3.76	12,780	48,053	1,160,496	May 22 01:19 PM
Townsend Adam J.	Former Officer	May 12 '25	Proposed Sale	17.76	220,961	3,924,267		May 12 02:22 PM
Chopas James George	VP/Chief Accounting Officer	Mar 17 '25	Sale	24.82	183	4,543	47,955	Mar 18 12:27 PM
Chopas James George	Officer	Mar 17 '25	Proposed Sale	24.82	183	4,543		Mar 17 03:18 PM
Watson David O.	General Counsel	Mar 05 '25	Sale	25.10	5,569	139,789	138,730	Mar 06 05:17 PM
DAVID OSBORNE WATSON	Officer	Mar 05 '25	Proposed Sale	25.10	5,569	139,789		Mar 05 04:22 PM
DeLong Mark Jeffrey	Chief Business & Strat Officer	Feb 11 '25	Sale	28.54	363	10,360	83,945	Feb 12 01:59 PM
DeLong Mark Jeffrey	Officer	Feb 11 '25	Proposed Sale	28.54	363	10,360		Feb 11 03:13 PM
Watson David O.	General Counsel	Jan 29 '25	Sale	29.52	695	20,519	144,299	Jan 30 12:20 PM
Townsend Adam J.	Chief Commercial Officer	Jan 29 '25	Sale	29.52	695	20,519	84,050	Jan 30 12:18 PM
Sullivan Timothy Eugene	Chief Financial Officer	Jan 29 '25	Sale	29.52	546	16,120	128,665	Jan 30 12:15 PM
Nicholson Nur	Chief Technical Officer	Jan 29 '25	Sale	29.52	825	24,357	83,664	Jan 30 12:13 PM
Lewis Karen	Chief People Officer	Jan 29 '25	Sale	29.52	364	10,747	70,251	Jan 30 12:12 PM
Eisele Jeffrey	Chief Development Officer	Jan 29 '25	Sale	29.52	278	8,208	55,312	Jan 30 12:10 PM
Deschatelets Pascal	Chief Scientific Officer	Jan 29 '25	Sale	29.52	826	24,386	1,147,716	Jan 30 12:07 PM
Francois Cedric	Chief Executive Officer	Jan 29 '25	Sale	29.52	2,824	83,375	415,695	Jan 30 12:03 PM
DeLong Mark Jeffrey	Chief Business & Strat Officer	Jan 29 '25	Sale	29.52	365	10,776	84,308	Jan 30 12:01 PM
Townsend Adam J.	Officer	Jan 29 '25	Proposed Sale	29.52	695	20,519		Jan 29 03:42 PM
Sullivan Timothy Eugene	Officer	Jan 29 '25	Proposed Sale	29.52	546	16,120		Jan 29 03:26 PM
Lewis Karen	Officer	Jan 29 '25	Proposed Sale	29.52	364	10,747		Jan 29 03:22 PM
Nicholson Nur	Officer	Jan 29 '25	Proposed Sale	29.52	825	24,357		Jan 29 03:18 PM
DeLong Mark Jeffrey	Officer	Jan 29 '25	Proposed Sale	29.52	365	10,776		Jan 29 03:17 PM
Watson David O.	Officer	Jan 29 '25	Proposed Sale	29.52	695	20,519		Jan 29 03:16 PM
Francois Cedric	Officer	Jan 29 '25	Proposed Sale	29.52	2,824	83,375		Jan 29 03:16 PM
Eisele Jeffrey	Officer	Jan 29 '25	Proposed Sale	29.52	278	8,208		Jan 29 03:12 PM
Deschatelets Pascal	Officer	Jan 29 '25	Proposed Sale	29.52	826	24,386		Jan 29 03:11 PM
Watson David O.	General Counsel	Jan 22 '25	Sale	30.43	3,323	101,104	144,994	Jan 23 03:41 PM
Townsend Adam J.	Chief Commercial Officer	Jan 22 '25	Sale	30.43	3,323	101,104	84,745	Jan 23 03:39 PM
Sullivan Timothy Eugene	Chief Financial Officer	Jan 22 '25	Sale	30.43	3,088	93,954	129,211	Jan 23 03:37 PM
Nicholson Nur	Chief Technical Officer	Jan 22 '25	Sale	30.43	3,948	120,120	84,489	Jan 23 03:31 PM
Lewis Karen	Chief People Officer	Jan 22 '25	Sale	30.43	1,751	53,275	70,615	Jan 23 03:29 PM
Francois Cedric	Chief Executive Officer	Jan 22 '25	Sale	30.43	13,551	412,296	418,519	Jan 23 03:28 PM
Eisele Jeffrey	Chief Development Officer	Jan 22 '25	Sale	30.43	1,291	39,279	55,590	Jan 23 03:26 PM
Deschatelets Pascal	Chief Scientific Officer	Jan 22 '25	Sale	30.43	3,948	120,120	1,148,542	Jan 23 03:25 PM
DeLong Mark Jeffrey	Chief Business & Strat Officer	Jan 22 '25	Sale	30.43	1,396	42,474	84,673	Jan 23 03:23 PM
Chopas James George	VP/Chief Accounting Officer	Jan 22 '25	Sale	30.43	1,096	33,346	48,138	Jan 23 03:19 PM
Francois Cedric	Officer	Jan 22 '25	Proposed Sale	30.43	13,551	412,296		Jan 22 04:00 PM
Watson David O.	Officer	Jan 22 '25	Proposed Sale	30.43	3,323	101,104		Jan 22 03:56 PM
Lewis Karen	Officer	Jan 22 '25	Proposed Sale	30.43	1,751	53,275		Jan 22 03:52 PM
Sullivan Timothy Eugene	Officer	Jan 22 '25	Proposed Sale	30.43	3,088	93,954		Jan 22 03:51 PM
Deschatelets Pascal	Officer	Jan 22 '25	Proposed Sale	30.43	3,948	120,120		Jan 22 03:45 PM
Townsend Adam J.	Officer	Jan 22 '25	Proposed Sale	30.43	3,323	101,104		Jan 22 03:45 PM
DeLong Mark Jeffrey	Officer	Jan 22 '25	Proposed Sale	30.43	1,396	42,474		Jan 22 03:44 PM
Eisele Jeffrey	Officer	Jan 22 '25	Proposed Sale	30.43	1,291	39,279		Jan 22 03:43 PM
Chopas James George	Officer	Jan 22 '25	Proposed Sale	30.43	1,096	33,346		Jan 22 03:42 PM
Nicholson Nur	Officer	Jan 22 '25	Proposed Sale	30.43	3,948	120,120		Jan 22 03:39 PM
Watson David O.	General Counsel	Jan 17 '25	Sale	29.96	2,201	65,938	105,555	Jan 21 04:14 PM
Townsend Adam J.	Chief Commercial Officer	Jan 17 '25	Sale	29.96	2,201	65,938	88,068	Jan 21 04:12 PM
Sullivan Timothy Eugene	Chief Financial Officer	Jan 17 '25	Sale	29.96	1,730	51,828	86,370	Jan 21 04:11 PM
Nicholson Nur	Chief Technical Officer	Jan 17 '25	Sale	29.96	2,145	64,260	52,011	Jan 21 04:09 PM
Lewis Karen	Chief People Officer	Jan 17 '25	Sale	29.96	1,241	37,178	43,858	Jan 21 04:07 PM
Francois Cedric	Chief Executive Officer	Jan 17 '25	Sale	29.96	6,007	179,959	301,408	Jan 21 04:04 PM
Deschatelets Pascal	Chief Scientific Officer	Jan 17 '25	Sale	29.96	750	22,469	1,137,445	Jan 21 04:02 PM
DeLong Mark Jeffrey	Chief Business & Strat Officer	Jan 17 '25	Sale	29.96	1,235	36,998	57,561	Jan 21 03:59 PM
Chopas James George	VP/Chief Accounting Officer	Jan 17 '25	Sale	29.96	715	21,420	36,643	Jan 21 03:56 PM
Baumal Caroline	Chief Medical Officer	Jan 17 '25	Sale	29.96	1,853	55,513	53,707	Jan 21 03:54 PM
Townsend Adam J.	Officer	Jan 17 '25	Proposed Sale	29.96	2,201	65,938		Jan 17 04:38 PM
Deschatelets Pascal	Officer	Jan 17 '25	Proposed Sale	29.96	750	22,469		Jan 17 04:35 PM
Nicholson Nur	Officer	Jan 17 '25	Proposed Sale	29.96	2,145	64,260		Jan 17 04:32 PM
Chopas James George	Officer	Jan 17 '25	Proposed Sale	29.96	715	21,420		Jan 17 04:29 PM
Francois Cedric	Officer	Jan 17 '25	Proposed Sale	29.96	6,007	179,959		Jan 17 04:27 PM
Watson David O.	Officer	Jan 17 '25	Proposed Sale	29.96	2,201	65,938		Jan 17 04:20 PM
Baumal Caroline	Officer	Jan 17 '25	Proposed Sale	29.96	1,853	55,513		Jan 17 04:18 PM
Lewis Karen	Officer	Jan 17 '25	Proposed Sale	29.96	1,241	37,178		Jan 17 04:16 PM
Sullivan Timothy Eugene	Officer	Jan 17 '25	Proposed Sale	29.96	1,730	51,828		Jan 17 04:16 PM
DeLong Mark Jeffrey	Officer	Jan 17 '25	Proposed Sale	29.96	1,235	36,998		Jan 17 04:14 PM
Watson David O.	General Counsel	Jan 13 '25	Sale	28.70	4,965	142,506	107,756	Jan 14 04:30 PM
Townsend Adam J.	Chief Commercial Officer	Jan 13 '25	Sale	28.70	2,685	77,065	90,269	Jan 14 04:29 PM
Sullivan Timothy Eugene	Chief Financial Officer	Jan 13 '25	Sale	28.70	2,170	62,284	88,100	Jan 14 04:25 PM
Nicholson Nur	Chief Technical Officer	Jan 13 '25	Sale	28.70	2,632	75,544	54,156	Jan 14 04:22 PM
Lewis Karen	Chief People Officer	Jan 13 '25	Sale	28.70	1,599	45,895	45,099	Jan 14 04:20 PM
Francois Cedric	Chief Executive Officer	Jan 13 '25	Sale	28.70	6,247	179,302	307,415	Jan 14 04:18 PM
Eisele Jeffrey	Chief Development Officer	Jan 13 '25	Sale	28.70	264	7,577	56,881	Jan 14 04:15 PM
Deschatelets Pascal	Chief Scientific Officer	Jan 13 '25	Sale	28.70	2,288	65,670	1,138,195	Jan 14 04:14 PM
DeLong Mark Jeffrey	Chief Business & Strat Officer	Jan 13 '25	Sale	28.70	1,599	45,895	58,796	Jan 14 04:10 PM
Chopas James George	VP/Chief Accounting Officer	Jan 13 '25	Sale	28.70	783	22,474	37,358	Jan 14 04:09 PM
Lewis Karen	Officer	Jan 13 '25	Proposed Sale	28.70	1,627	46,689		Jan 13 06:15 PM
Sullivan Timothy Eugene	Officer	Jan 13 '25	Proposed Sale	28.70	2,209	63,390		Jan 13 06:13 PM
Townsend Adam J.	Officer	Jan 13 '25	Proposed Sale	28.70	2,734	78,456		Jan 13 06:09 PM
Eisele Jeffrey	Officer	Jan 13 '25	Proposed Sale	28.70	264	7,576		Jan 13 06:07 PM
Nicholson Nur	Officer	Jan 13 '25	Proposed Sale	28.70	2,681	76,935		Jan 13 06:05 PM
Watson David O.	Officer	Jan 13 '25	Proposed Sale	28.70	5,056	145,088		Jan 13 06:02 PM
Francois Cedric	Officer	Jan 13 '25	Proposed Sale	28.70	6,357	182,422		Jan 13 06:02 PM
Deschatelets Pascal	Officer	Jan 13 '25	Proposed Sale	28.70	2,331	66,891		Jan 13 06:00 PM
DeLong Mark Jeffrey	Officer	Jan 13 '25	Proposed Sale	28.70	1,627	46,689		Jan 13 05:56 PM
Chopas James George	Officer	Jan 13 '25	Proposed Sale	28.70	798	22,900		Jan 13 05:55 PM
Baumal Caroline	Chief Medical Officer	Jan 06 '25	Sale	33.81	2,816	95,215	55,560	Jan 08 04:03 PM
Baumal Caroline	Officer	Jan 06 '25	Proposed Sale	33.81	2,816	95,213		Jan 06 03:17 PM
Eisele Jeffrey	Chief Development Officer	Dec 23 '24	Sale	33.09	63	2,085	57,145	Dec 27 04:06 PM
Eisele Jeffrey	Officer	Dec 23 '24	Proposed Sale	33.09	63	2,085		Dec 23 03:09 PM
Watson David O.	General Counsel	Dec 11 '24	Sale	34.23	5,000	171,175	112,721	Dec 13 04:15 PM
DAVID OSBORNE WATSON	Officer	Dec 11 '24	Proposed Sale	34.23	5,000	171,175		Dec 11 04:48 PM
Dunlop A. Sinclair	Director	Sep 23 '24	Option Exercise	13.19	4,600	60,674	152,126	Sep 24 04:20 PM
Dunlop A. Sinclair	Director	Sep 16 '24	Sale	36.23	37,000	1,340,597	100,000	Sep 17 05:21 PM
Chopas James George	VP/Chief Accounting Officer	Sep 16 '24	Sale	36.21	192	6,952	38,141	Sep 17 04:08 PM
Chopas James George	Officer	Sep 16 '24	Proposed Sale	36.21	192	6,952		Sep 16 03:22 PM
Chopas James George	VP/Chief Accounting Officer	Sep 03 '24	Sale	39.49	550	21,720	38,333	Sep 04 04:07 PM
Chopas James George	Officer	Sep 03 '24	Proposed Sale	39.49	550	21,720		Sep 03 03:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APLS

Apellis Pharmaceuticals Inc

Upgrade your FINVIZ experience